Medtronic, FDA and Affera

Medtronic’s Affera PFA snags FDA approval
Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s greenlight for its Affera mapping and ablation system with the Sphere-9 catheter. Affera brings the first radiofrequency/PFA device to the cardiac ablation market and ups the ante in the PFA competition.
Medtronic wins FDA approval for Affera mapping and ablation system
Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.
FDA approves Medtronic’s Affera mapping and ablation system with Sphere-9 catheter
This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.
Medtronic’s Innovative Affera System Gains FDA Approval, Boosting EP Market Prospects
Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report) and keeping the price
FDA approves Medtronic's Affera all-in-one pulsed field ablation system
Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again. | Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation for afib,
FDA approves Medtronic’s Affera cardiac mapping and ablation system and Sphere-9 catheter
Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA and RF energy.
Medtronic’s Affera ablation system granted FDA approval
Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping
Medtronic Gets FDA Approval for Affera Technology
Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter. The healthcare company said it is now the first and only company with two pulsed field ablation technologies available for patients with the heart-disease persistent atrial fibrillation following the Dec.
Medtronic Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to ...
Medtronic (MDT) Receives a Hold from Piper Sandler
Piper Sandler analyst Matthew O’Brien maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of ...
Becker's Hospital Review6h
FDA issues critical recalls for Baxter ventilators, Medtronic pumps and Boston Scientific device
The FDA recently announced critical recalls on several widely used medical devices, including Life2000 ventilators, Medtronic's MiniMed insulin pumps and Boston Scientific's Obsidio conformable ...
Medtronic plc (NYSE:MDT) Shares Sold by Beese Fulmer Investment Management Inc.
Beese Fulmer Investment Management Inc. cut its position in Medtronic plc (NYSE:MDT – Free Report) by 24.4% during the third ...
FierceBiotech1d
Medtronic expands reach of its latest TAVR valve with European approval
After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...
Hosted on MSN2d
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
Medtronic (MDT) closed at $91.12 in the latest trading session, marking a +0.1% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.05% for the day. Elsewhere, the ...
MassDevice1d
Medtronic wins CE mark for Evolut FX+
Medtronic announced today that it received CE mark approval for its Evolut FX+ transcatheter aortic valve implantation (TAVI) ...
Philips announces strategic advocacy partnership with Medtronic
Royal Philips (PHG) and Medtronic Neurovascular announced a strategic advocacy partnership. As leaders in stroke diagnosis and treatment, the ...